Alnylam Pharmaceuticals

(Photo credit MIGUEL MEDINA/AFP/Getty Images)

Genzyme Jumps Into Rapidly Growing Business Of Genetic Medicines

Genzyme is spending $700 million dollars to buy a chunk of Alnylam Pharmaceuticals of Cambridge — a much smaller company that been moving rapidly toward commercializing treatments for rare genetic diseases.

01/13/2014

Follow

Get every new post delivered to your Inbox.

Join 2,162 other followers